KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biocryst Pharmaceuticals (BCRX) Capital Leases (2023 - 2025)

Biocryst Pharmaceuticals (BCRX) has disclosed Capital Leases for 3 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Capital Leases fell 32.16% year-over-year to $1.4 million, compared with a TTM value of $1.4 million through Dec 2025, down 32.16%, and an annual FY2025 reading of $1.4 million, down 32.16% over the prior year.
  • Capital Leases was $1.4 million for Q4 2025 at Biocryst Pharmaceuticals, down from $2.3 million in the prior quarter.
  • Across five years, Capital Leases topped out at $2.8 million in Q4 2023 and bottomed at $1.4 million in Q4 2025.
  • Average Capital Leases over 3 years is $2.2 million, with a median of $2.1 million recorded in 2024.
  • The sharpest move saw Capital Leases decreased 25.34% in 2024, then plummeted 32.16% in 2025.
  • Year by year, Capital Leases stood at $2.8 million in 2023, then fell by 25.34% to $2.1 million in 2024, then crashed by 32.16% to $1.4 million in 2025.
  • Business Quant data shows Capital Leases for BCRX at $1.4 million in Q4 2025, $2.3 million in Q1 2025, and $2.1 million in Q4 2024.